Source link : https://www.newshealth.biz/health-news/overall-survival-data-confirm-benefit-of-pembro-in-tnbc/
BARCELONA, Spain — Long-awaited overall survival data from the KEYNOTE-522 trial has lifted spirits in the triple-negative breast cancer (TNBC) community. The trial confirmed the survival benefit of adding perioperative pembrolizumab to standard chemotherapy in stage II or III disease. “We reduced the risk of death by 34%, which is the first time we have […]
Author : News Health
Publish date : 2024-09-18 12:48:20
Copyright for syndicated content belongs to the linked Source.
inHealth